Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Common Stock Issued

Cash raised by issuing new shares.

Canopy Growth CorporationNASDAQ: CGC

Common Stock Issued · Q4 FY2025 · quarter ended Mar 2026

Common stock issued outflow shrinks to CA$0

Q4 FY2025 common stock issued was CA$0, compared with CA$129.4M a year earlier. Trailing-twelve-month common stock issued was CA$408.55M. Over 3 fiscal years it compounded at +609.2% a year.

Context

  • Common stock issued amounted to 77.4% of revenue in FY2025, down 65.9 pp from a year earlier.
  • Common stock issued increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly common stock issued holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$102.14M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0-100.0% QoQ
Last fiscal yearMar 2026
CA$374.17M-2.9% YoY
LTMMar 2026
CA$408.55M+6.0% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-2.9%——
3-year CAGR+609.2%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

CAD · from the cash flow

Latest · FY2025
374.17M CAD
Year-over-year change
-2.9%
4-year CAGR
+243.1%

Common Stock Issued vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.0% is the 5th highest of 8, against a peer median of +420.9%.
  • Common stock issued amounts to 130.8% of revenue for CGC, versus a peer median of 1.8%.
CGC Competitors
Common Stock Issued for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$408.55M CAD+6.0%+609.2%130.8%
BIOABioAge Labs, Inc.LTM Mar 2026$143.89M USD+420.9%+640.5%1394.8%
CABACabaletta Bio, Inc.LTM Mar 2026$135.94M USD+1085.7%+48.0%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$102.13M USD+7762.1%+65.6%329448.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$58.03M USD-22.6%—693.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$9.94M CAD+1112.0%-48.6%3.2%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$210K USD-78.1%-71.7%0.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026$144K USD-99.1%-21.7%0.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$8K USD——0.0%
DHDefinitive Healthcare Corp.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CGC) —+420.9%+13.2%1.8%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Net Income(258.91M)(3.08B)(483.68M)(604.14M)(366.64M)
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
Deferred Income Tax(8.95M)(5.73M)12.33M7.14M0
Stock-Based Compensation46.69M25.32M14.18M(4.21M)5.95M
Change in Working Capital205M58.97M3.97M(31.97M)20.68M
Accounts Receivables16.15M6.24M(3.75M)(4.49M)25.69M
Inventory204.22M68.44M1.03M(17.72M)3.71M
Accounts Payables00000
Other Working Capital(15.37M)(15.71M)6.68M(9.77M)(8.72M)
Other Non-Cash Items(640.58M)2.36B118.08M424.3M200.17M
Operating Cash Flow(545.81M)(557.55M)(281.95M)(165.75M)(88.98M)
Capital Expenditures(48.11M)(10.45M)(4M)(11.28M)(7.44M)
Acquisitions (Net)103.2M14.93M(955K)(6.97M)0
Purchases of Investments(379.41M)(67.15M)(347K)(95.34M)0
Sales of Investments546.01M502.59M78.55M16.43M26.5M
Other Investing Activities(2.3M)(7.88M)167.79M48.9M(48.83M)
Investing Cash Flow230.82M433.38M241.59M(47.79M)(29.77M)
Debt Repayment(50.76M)16.98M(509.78M)(220.78M)(24.62M)
Common Stock Issued2.7M1.05M81.06M385.39M374.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.53M(37.72M)(36.34M)(15.96M)114.02M
Financing Cash Flow(45.53M)(19.69M)(465.06M)148.66M463.57M
Effect of Forex Changes(18.12M)44.86M(1.29M)8.39M5.05M
Net Change in Cash(378.65M)(99M)(506.71M)(56.49M)349.86M
Free Cash Flow(593.92M)(568M)(285.95M)(177.03M)(96.42M)

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.